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Infliximab is an effective treatment for steroid and immunomodulator refactory ulcerative colitis. The pivotal clinical trials ACT1 and ACT2 showed that induction with 5mg/kg gives a clinical response in 64 – 69% of patients, double that of placebo. While statistically significant response rates are maintained at 54 weeks only a minority of patients (26% versus 9% for placebo, p<0.006) achieve the important clinical end point of steroid free remission at one year (New England Journal of Medicine 2005;353:2462-76). Infliximab is also effective in steroid-resistant severe UC (Gastroenterology 2005;128:1805-11). However, clinicians must balance this therapeutic advance against knowledge of the rare but potentially serious complications of auto-immunity, opportunistic infection and sepsis and malignancy (Gastroenterology 2004;126:19-31). There is a need therefore for accurate predictors of an individuals’ response to Infliximab allowing rationale prescribing tailoring biological therapy to those most likely to respond and avoiding risks and expense in those least likely to benefit.

In this important study Arijs and co-workers identified ‘panels’ of genes whose expression levels in mucosal biopsies taken prior to Infliximab therapy could predict an individuals’ subsequent response. Biopsy samples were obtained at sigmoidoscopy from 2 cohorts comprising 24 and 21 Infliximab naive patients with ulcerative colitis immediately prior to their first Infliximab dose. At 4-8 weeks after treatment with either single dose or standard 3 dose Infliximab induction individuals were characterised as either responders or non-responders using a strict but objective and reproducible definition of remission which included mucosal healing. A commercially available ‘chip’ was used to assess the relative expression of genes within the mucosa with 9183 gene probes compared between responders and non-responders after rigorous quality control steps. This genome wide approach allows a hypothesis free analysis of the genes investigated with no prior knowledge of their function. Having identified genes expressed at significantly higher or lower levels in responders than in non-responders, and having confirmed the results by quantitative PCR, the researchers assessed the accuracy of panels of these differentially expressed genes to predict in advance an individuals’ response to Infliximab. 

In total, 33% and 54% of individuals in cohorts A and B were defined as responders to Infliximab. A total of 74 gene probes from 53 different genes were found to be consistently expressed at significantly lower levels in responders than in non-responders in both panels. A degree of redundancy on the chip used for this analysis meant that some genes were analysed using more than one probe with strikingly consistent results increasing confidence in their veracity. Initial tests within each cohort showed some promise that panels consisting of expression levels of the most differentially expressed 5 or 20 genes could predict an individual’s subsequent response. When the panel of genes identified in cohort A was used to predict the response in cohort B and vice versa accuracies of only 50-71% were obtained. The authors therefore proceeded to study the top five genes from both cohorts combined. Elevated levels of the top five most differentially expressed genes, Osteoprotegerin, Stanniocalcin-1, Cyclooxigenase-2 (also known as prostaglandin-endoperoxidase synthase 2), Interleukin receptor alpha2 and interleukin 11, predicted failure to respond to Infliximab with 89% accuracy.

Comment. This study is an important advance in our understanding of the pathobiology of ulcerative colitis and its pharmacogenomics. Not only is this a vital first step in the development of genomics to predict response to Infliximab, its throws light on the pathogenic pathways responsible for TNF-driven IBD. Future studies might improve consistency of results by using a single Infliximab induction regime and assessing response and mucosal healing at the same time point in all individuals. Alternative definitions of response at other time points might prevent heterogeneity as partial responders going on to fully respond will be more accurately allocated to the correct group. Another possibility is that the current results could be used in conjunction with other predictors of clinical response to improve accuracy. 

In ulcerative colitis no genomic studies have demonstrated replicable association between genetic variants and response to anti-TNF therapy. For the related condition Crohn’s disease investigations of association between infliximab response and variation in disease susceptibility genes TNF, MDR1, NOD2 and the IBD5 risk haplotype have either been negative or not been confirmed in larger panels. One study of 21 apoptosis related polymorphisms in 287 patients with Crohn’s disease identified variants in Fas ligand and caspase-9 to be modestly associated with response to Infliximab (Alimentary Pharmacol Ther 2005 2005;22:613-26). This finding awaits independent verification and investigation in ulcerative colitis. An initial report of association with biological response to Infliximab at a polymorphism in FCGR3A (the gene coding for FcgammaRIIIa, which is involved in antibody-dependent cell-mediated cytotoxicity) was not confirmed in a larger panel from the ACCENT I study cohort (Pharmacogenet Genomics. 2006 Dec;16(12):911-4.) 

A number of non-genetic, serological and clinical predictors of clinical response of Ulcerative colitis to Infliximab have been identified. Younger patients respond better than older patients. Patients with positive pANCA but negative ASCA serology have a poorer response that those with other serotypes (55% vs 76%, p = 0.047). Of interest neither CRP levels nor treatment with thiopurines predicted response in this single centre retrospective study of 100 consecutive ulcerative colitis patients (Inflammatory Bowel Disease 2007;13:123-8). 

Measurement of trough levels of Infliximab and antibodies to Infliximab in serum has also been shown to account for either primary failure of response or subsequent loss of response to Infliximab. In one study Infliximab was undetectable in the serum of 39% of patients with ulcerative colitis. The presence of detectable Infliximab in serum predicted higher remission rates (69 vs 15%) (Gut 2010;59:49-54). In another study dose escalation resulted in clinical response 86% of patients with low serum levels of Infliximab whereas substitution of Infliximab with another anti-TNF agent only gained useful response in 33% of patients. Changing therapy to another anti-TNF agent in patients with antibodies can result in complete or partial response in 92% of patients (American Journal of Gastroenterology 2010;105:1133-9). 

In the current study the increased expression of the 5 top genes identified predicted failure of response to Infliximab. It is interesting, and perhaps unanticipated, that three of the genes, Osteoprotegrin, Staniocalcin and IL-11, are characterised in the literature as “anti-inflammatory” rather than “pro-inflammatory”. Intuition might forecast that genes associated with lack of response to Infliximab might be pro-inflammatory or associated with pathways that inactivate Infliximab. One possibility is that these “anti-inflammatory” genes are markers of colitis that do not respond to endogenous anti-inflammatory feedback loops. 

Osteoprotegrin (OPG, TNFRSFIIB) is a decoy receptor for receptor activator of NF-κB (RANKL). RANKL bound to its cognate receptor RANK (receptor activator of NF-κB) increases intestinal dendritic cell survival, cytokine production and stimulates bone resorption. OPG acts in negative feedback loops and can prevent the effects of RANKL/RANK and has been shown to ameliorate the spontaneous colitis that occurs in IL12-/- mice (Immunity 2003;19:849-61). This form of colitis resembles human ulcerative colitis. OPG also antagonizes the effect of TNF related apoptosis inducing ligand (TRAIL)(American Journal of Physiology 2004;287:G836-44). This beneficial effect of OPG has prompted some to propose OPG as a treatment for human colitis (Gut 2005;54:1345-6). It is therefore surprising that high levels of OPG predict resistance of UC to treatment with Infliximab. Stanniocalcin was originally identified as a hormone secreted by the corpuscles of Stannius in bony fish. In mammals it acts in a paracrine rather than endocrine fashion and has a variety of effects including being anti-inflammatory. It has been shown to inhibit activation of NF-κB and JNK to reduce macrophage migration and to prevent increases in vascular permeability caused by TNF- and NF-κB (Arteriosclerosis Thrombosis and Vascular Biology 2008;28:906-12). IL-11 is a pluripotent Il-6 type cytokine with potent anti-inflammatory properties including inhibition of TNF-, IL-1, Il-6 and IL-12 by macrophages (Haematologia 2002;87:373-80). It has been tested as a therapy for graft-versus-host disease. Its receptor IL-11R plays a central role in the inflammatory and remodelling action of IL-13 (Journal of Immunology 2005;174:2305-13).

The other two genes are pro-inflammatory. The IL-13 receptor alpha2 (IL13R2) mediates the fibrotic effects of the TH2 cytokine IL13 by acting as an IL13 receptor stimulating production of TGF- by monocytes and macrophages (Nature Medicine 2006;12:99-106). Cyclo-oxygenase 2 (COX-2) is an inducible cyclo-oxygenase that sits at the apex of the prostaglandin cascade and catalyses that conversion of arachidonic acid to prostaglandin H2. It is induced by a range of inflammatory mediators including TNF- and IL-1. Its prostaglandin products have been extensively documented to drive both the inflammatory response and to accelerate neoplasia including the generation of colonic adenomas and cancer (Oncogene 2010;29:781-8). 

Collectively these studies suggest that in the future a far more rational and targeted approach to Infliximab therapy will be possible. Building on this pioneering study by Arijs and colleagues, gene expression and genomic data from individual patients will be analyzed to determine if they can respond to anti-TNF therapy and perhaps combined with additional genomic information to determine who are at risk of serious adverse reactions. One can envisage that genetic information might be combined with serological, histopathological and clinical information to produce a “response score” to determine in whom anti-TNF therapy will be efficacious and safe. The choice and dose of anti-TNF agent will be guided by blood levels and monitoring of immunological response against the anti-TNF agent. The development of anti-TNF therapy was a major breakthrough in the treatment of IBD. Pharmacogenetics and other complimentary approaches promise to take anti-TNF therapy up to the next level.





